The anti-CD38 mAb daratumumab (Darzalex) is the first new agent with a different mode of action against multiple myeloma to be recommended by the PBAC for 13 years. Watch as a panel of experts discuss its potential role in the treatment of myeloma patients at first relapse, and how its availability may influence current front line approaches to patient management.

Hosted by:

Professor H. Miles Prince AM. MBBS (Hons) MD FRACP FRCPA AFRCMA MACD FAHMS. Professor, University of Melbourne. Professor, Monash University; Professor/Director of Molecular Oncology and Cancer Immunology, Epworth Healthcare Cell Therapies, Peter MacCallum Cancer Centre.

With special guests:

Professor Gordon Cook. Professor of Haematology & Myeloma Studies; Clinical Director (Haematology), Leeds Institute of Clinical Trials Research, Leeds Cancer Centre, UK.

Doctor Wojit Janowski. Clinical and laboratory haematologist, Calvary Mater Newcastle, Hunter Cancer Centre, University of Newcastle, NSW Pathology.

Ms Nella Combe. Manager – Nursing and Patient Services at Myeloma Foundation Of Australia; Myeloma Clinical Nurse Consultant, Peter MacCallum Cancer Centre.

This program was developed independently by the limbic and MSAG. Thanks to Janssen-Cilag Pty Ltd for providing a non-restrictive educational grant that made this possible.